Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges

Wang, Zhonglei; Yang, Liyan

doi:10.1002/jmv.27517

Cited by 40 publications

(28 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COVID-19 pandemic is ongoing and promising curative treatments do not yet exist (36,37). Meanwhile, the sequelae of this infection have posed a considerable threat to global health and economic development.…”

Section: Discussionmentioning

confidence: 99%

Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue

Wang

Yang

2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue

Wang

Yang

2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

“…Tautomeric variants of molnupiravir can cause mutations during G‐to‐A and C‐to‐U transitions and finally lead to inhibition of viral replication. 31 Moreover, molnupiravir with favipiravir 32 or dihydroorotate dehydrogenase inhibitors such as IMU‐838/vidofludimus and BAY2402234 33 has shown synergistic effects in preclinical studies, yet to be clinically established. However, molnupiravir lacks ADR data as it is hard to distinguish between treatment‐related adverse events and Covid‐19‐related adverse events.…”

Section: Molnupiravirmentioning

confidence: 99%

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Islam

Hasan

Rahman

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic. Here we aimed for a comparative evaluation of authorized drugs for treating Covid‐19 patients. Methods We searched in PubMed and Google Scholar using keywords and terms such as Covid, SARS‐CoV‐2, Coronavirus disease 2019, therapeutic management, hospitalized Covid‐19 patients, Covid‐19 treatment. We also gathered information from reputed newspapers, web portals, and websites. We thoroughly observed, screened, and included the studies relevant to our inclusion criteria. We included only the United States Food and Drug Administration (FDA) authorized drugs for this review. Results We found that molnupiravir and paxlovid are available for oral use, and remdesivir is for only hospitalized patients. Paxlovid is a combination of nirmatrelvir and ritonavir, nirmatrelvir is a protease inhibitor (ritonavir increases the concentration of nirmatrelvir), and the other two (remdesivir and molnupiravir) are nucleoside analog prodrugs. Remdesivir and molnupiravir doses do not need to adjust in renal and hepatic impairment. However, the paxlovid dose adjustment is required for mild to moderate renal or hepatic impaired patients. Also, the drug is not allowed for Covid‐19 patients with severe renal or hepatic impairment. Preliminary studies showed oral antiviral drugs significantly reduce hospitalization or death among mild to severe patients. Moreover, the US FDA has approved four monoclonal antibodies for Covid‐19 treatment. Studies suggest that these drugs would reduce the risk of hospitalization or severity of symptoms. World Health Organization strongly recommended the use of corticosteroids along with other antiviral drugs for severe or critically hospitalized patients. Conclusion All authorized drugs are effective in inhibiting viral replication for most SARS‐CoV‐2 variants. Therefore, along with vaccines, these drugs might potentially aid in fighting the Covid‐19 pandemic.

show abstract

“… 88 , 89 RNA-dependent RNA-polymerase (RdRp) is one of the significant druggable targets of SARS-COV-2. 90 , 91 Many investigations have been conducted to analyze the role of flavonoids concerning RdRp. For example, Singh et al 92 used a molecular docking method to target RdRp of SARS-COV-2.…”

Section: Functional Food Ingredients Were Effective In Virus Infectionsmentioning

confidence: 99%

A Review on the Antiviral Activity of Functional Foods Against COVID-19 and Viral Respiratory Tract Infections

Omer¹,

Khorshidi²,

Mortazavi³

et al. 2022

IJGM

View full text Add to dashboard Cite

Due to the absence of successful therapy, vaccines for protection are continuously being developed. Since vaccines must be thoroughly tested, viral respiratory tract infections (VRTIs), mainly coronaviruses, have seriously affected human health worldwide in recent years. In this review, we presented the relevant data which originated from trusted publishers regarding the practical benefits of functional foods (FFs) and their dietary sources, in addition to natural plant products, in viral respiratory and COVID-19 prevention and immune-boosting activities. As a result, FFs were confirmed to be functionally active ingredients for preventing COVID-19 and VRTIs. Furthermore, the antiviral activity and immunological effects of FFs against VRTIs and COVID-19 and their potential main mechanisms of action are also being reviewed. Therefore, to prevent COVID-19 and VRTIs, it is critical to identify controlling the activities and immune-enhancing functional food constituents as early as possible. We further aimed to summarize functional food constituents as a dietary supplement that aids in immune system boosting and may effectively reduce VRTIs and COVID-19 and promote therapeutic efficacy.

show abstract

Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges

Cited by 40 publications

References 145 publications

Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue

Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue

Comparative evaluation of authorized drugs for treating Covid‐19 patients

A Review on the Antiviral Activity of Functional Foods Against COVID-19 and Viral Respiratory Tract Infections

Contact Info

Product

Resources

About